Europe
There has been a flurry of expansion activity in the life sciences industry as biopharma and diagnostic companies expand manufacturing sites. Here’s a look.
A quick overview of life science companies scooping up some summer spending money this week.
Regeneron and AstraZeneca are looking to research, develop, and eventually commercialize a new drug that targets GPR75, the gene associated with obesity.
Moderna continues to assess its COVID-19 vaccine in juveniles, the company is expanding the study to include protocols to detect the potential of rare side effects, including heart inflammation.
The company announced its Malaria project, part of the “eradicateMalaria” initiative led by the kENUP Foundation.
Just as it was beginning to appear safe to return to maskless, pre-pandemic life, the Delta variant of the SARS-CoV-2 virus emerged. It is fast-spreading, more likely to lead to hospitalizations, and accounts for most of the breakout infections among fully vaccinated individuals.
It’s a busy week for GlaxoSmithKline, although much of it is related to the upcoming demerger of its Consumer Healthcare business. Here’s a look.
The FDA called for Iterum to conduct an additional clinical study that uses a different drug for comparison and to determine optimal dosing.
Lantern will reacquire the Irofulven program and evaluate its potential for advanced development to treat bladder and prostate cancers.
A vaccine for herpes is under development and Rational Vaccines are going to make this a reality very soon. Here’s everything you need to learn about it.
PRESS RELEASES